[go: up one dir, main page]

WO2013049307A3 - Développement d'une mémoire immunitaire améliorée par une inhibition de mtor des lymphocytes t ciblée par un aptamère - Google Patents

Développement d'une mémoire immunitaire améliorée par une inhibition de mtor des lymphocytes t ciblée par un aptamère Download PDF

Info

Publication number
WO2013049307A3
WO2013049307A3 PCT/US2012/057495 US2012057495W WO2013049307A3 WO 2013049307 A3 WO2013049307 A3 WO 2013049307A3 US 2012057495 W US2012057495 W US 2012057495W WO 2013049307 A3 WO2013049307 A3 WO 2013049307A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
immune memory
enhanced immune
mtor inhibition
memory development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/057495
Other languages
English (en)
Other versions
WO2013049307A2 (fr
WO2013049307A9 (fr
Inventor
Eli Gilboa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of WO2013049307A2 publication Critical patent/WO2013049307A2/fr
Anticipated expiration legal-status Critical
Publication of WO2013049307A3 publication Critical patent/WO2013049307A3/fr
Publication of WO2013049307A9 publication Critical patent/WO2013049307A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions pour l'induction ou l'amélioration de la mémoire de cellules immunitaires permettant une protection et un traitement hautement efficaces, faiblement toxiques et à plus longue durée contre une maladie. Les compositions potentialisent des cellules de mémoire immunitaire à longue durée, davantage que les cellules effectrices à courte durée de vie générées rapidement après la vaccination, et sont mieux équipées pour fournir une immunité protectrice.
PCT/US2012/057495 2011-09-30 2012-09-27 Développement d'une mémoire immunitaire améliorée par une inhibition de mtor des lymphocytes t ciblée par un aptamère Ceased WO2013049307A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541588P 2011-09-30 2011-09-30
US61/541,588 2011-09-30

Publications (3)

Publication Number Publication Date
WO2013049307A2 WO2013049307A2 (fr) 2013-04-04
WO2013049307A3 true WO2013049307A3 (fr) 2014-04-24
WO2013049307A9 WO2013049307A9 (fr) 2014-06-05

Family

ID=47996732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/057495 Ceased WO2013049307A2 (fr) 2011-09-30 2012-09-27 Développement d'une mémoire immunitaire améliorée par une inhibition de mtor des lymphocytes t ciblée par un aptamère

Country Status (1)

Country Link
WO (1) WO2013049307A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3148579T3 (pl) 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
CN105198790B (zh) * 2015-04-20 2018-02-16 范国煌 促进双阴性t细胞体外增殖的四环化合物
BR112017023849A2 (pt) 2015-05-07 2018-07-17 Agenus Inc. anticorpos anti-ox40 e métodos de uso dos mesmos
MX2018006477A (es) 2015-12-02 2018-09-03 Agenus Inc Anticuerpos y metodos de uso de estos.
RU2747822C2 (ru) 2016-03-14 2021-05-14 Ф. Хоффманн-Ля Рош Аг Олигонуклеотиды для понижения экспрессии pd-l1
EP3538152A4 (fr) 2016-11-09 2020-09-30 Agenus Inc. Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
CN107974433B (zh) * 2017-12-08 2020-12-01 新乡医学院 一种增强型抗肿瘤nk细胞及其制备方法和应用
CN108823211A (zh) * 2018-05-04 2018-11-16 中国医学科学院基础医学研究所 一种cd19核酸适配体及其应用
WO2020089811A1 (fr) 2018-10-31 2020-05-07 Novartis Ag Conjugué médicament-anticorps anti-dc-sign
WO2020102701A1 (fr) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Procédés de fabrication de lymphocytes t de phénotype th1/tc1
CN112807425A (zh) * 2021-01-14 2021-05-18 南方医科大学深圳医院 一种tTIM融合蛋白疫苗、制备方法及应用
CN120114579A (zh) * 2025-04-27 2025-06-10 南京中医药大学 一种人参细胞工程化肿瘤疫苗及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240732A1 (en) * 2007-10-01 2010-09-23 University Of Miami Aptamer-targeted sirna to prevent attenuation or suppression of a t cell function
US20110129496A1 (en) * 2008-08-05 2011-06-02 Emory University Use of mTOR Inhibitors to Enhance T Cell Immune Responses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240732A1 (en) * 2007-10-01 2010-09-23 University Of Miami Aptamer-targeted sirna to prevent attenuation or suppression of a t cell function
US20110129496A1 (en) * 2008-08-05 2011-06-02 Emory University Use of mTOR Inhibitors to Enhance T Cell Immune Responses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PASTOR ET AL.: "Targeting 4-1 BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers.", MOL THER, vol. 19, no. 10, October 2011 (2011-10-01), pages 1878 - 1886, XP008150757, DOI: doi:10.1038/mt.2011.145 *

Also Published As

Publication number Publication date
WO2013049307A2 (fr) 2013-04-04
WO2013049307A9 (fr) 2014-06-05

Similar Documents

Publication Publication Date Title
WO2013049307A3 (fr) Développement d'une mémoire immunitaire améliorée par une inhibition de mtor des lymphocytes t ciblée par un aptamère
WO2012129341A3 (fr) Détection d'une maladie chez les plantes
EP2544691A4 (fr) Composé, composition, et procédé pour protéger la peau contre la lumière visible à énergie élevée
PH12014502445B1 (en) Targeted modification of malate dehydrogenase
MX338980B (es) Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9.
PL3321355T3 (pl) Sposoby i kompozycje do klinicznego pozyskiwania komórek alogenicznych oraz zastosowania terapeutyczne
PL2608762T3 (pl) Kompozycje i sposoby do termomodulacji celowanej
WO2012033814A3 (fr) Bactériothérapie clostridiale environnementale et formulations associées et leurs procédés de fabrication et d'utilisation
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
BR112015004327A2 (pt) composições biodegradáveis, métodos e usos das mesmas
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2012054862A9 (fr) Agents, compositions et méthodes pour traiter le prurit et des troubles dermiques associés
GEP201706668B (en) Parenteral norovirus vaccine formulations
WO2012097185A3 (fr) Vaccin omv contre les infections par burkholderia
EP2596017A4 (fr) Protection croisée contre un pathogène, méthodes et compositions afférentes
EP2586462A4 (fr) Agent prophylactique ou d'amélioration pour maladies génétiques
LT2552484T (lt) Būdai ir kompozicijos, skirti paratiroidų lygiams sumažinti
ZA201306990B (en) Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
PL2694538T3 (pl) Sposoby terapeutyczne i profilaktyczne, zastosowania i kompozycje zawierające aneksynę a5
WO2013023059A3 (fr) Méthodes et compositions pour le traitement de maladies auto-immunes et inflammatoires
MX2013013891A (es) Sistema y metodo de tratamiento de agua anti-incrustaciones.
WO2009129208A3 (fr) Compositions et procédés permettant d'induire une réponse au stress du réticulum endoplasmique
WO2012154271A3 (fr) Procédé et cellules pour l'identification de régulateurs de la voie rig-i
WO2011102999A3 (fr) Thérapie ciblant spink1
WO2012116992A3 (fr) Utilisation orale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12835212

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12835212

Country of ref document: EP

Kind code of ref document: A2